Molecular Profiling to Predict Response to Treatment (phs001965)

The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI&#39;s Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled &quot;Identification of Genetic Changes Associated with Relapse and/or Adaptive Resistance in Patients Registered as Favorable Histology Wilms Tumor on AREN03B2&quot;, performs genomic characterization (WGS 30X, Total RNAseq, miRNAseq) on a discovery set of 70 trio cases (normal tissue, tumor tissue at time of diagnosis, tumor tissue at time of relapse) from patients who relapsed with Favorable Histology Wilms Tumor. Prioritized findings from the discovery set will be validated using Targeted Sequencing in an independent validation set of 47 relapse samples. The MP2PRT study is made available on AWS via the NIH STRIDES Initiative (<a href="https://aws.amazon.com/blogs/publicsector/aws-and-national-institutes-of-health-collaborate-to-accelerate-discoveries-with-strides-initiative/">https://aws.amazon.com/blogs/publicsector/aws-and-national-institutes-of-health-collaborate-to-accelerate-discoveries-with-strides-initiative/</a>).

分子特征分析以预测治疗反应（MP2PRT）计划属于美国国家癌症研究所（NCI）的癌症登月计划。该计划旨在对国家临床试验网络和国家癌症研究所社区肿瘤学研究计划中已完成的研究所收集的生物样本进行回顾性特征描述和分析。本研究题为《识别与有利于组织学Wilms肿瘤患者复发和/或适应性耐药相关的遗传变化》，对70例三联病例的发现集（正常组织、诊断时的肿瘤组织、复发时的肿瘤组织）进行基因组特征分析（WGS 30X，总RNA测序，miRNA测序）。发现集中的优先发现将通过针对独立验证集的47个复发样本进行靶向测序进行验证。MP2PRT研究通过美国国立卫生研究院STRIDES计划在AWS上提供，该计划旨在通过STRIDES倡议加速发现（<a href="https://aws.amazon.com/blogs/publicsector/aws-and-national-institutes-of-health-collaborate-to-accelerate-discoveries-with-strides-initiative/">https://aws.amazon.com/blogs/publicsector/aws-and-national-institutes-of-health-collaborate-to-accelerate-discoveries-with-strides-initiative/</a>）。